Trial Updates
Memo: Discussion of KESETT at Community Events Prior to CIRB review
Please see the memo from KESETT Leadership regarding the discussion of KESETT at community events prior to CIRB review: To: KESETT Sites From: KESETT Leadership Re: Discussion of KESETT at …
KESETT – New Resource in the Workbench
We have added a new resource to the KESETT workbench. You can find the archive of the slides presented at the monthly SIREN study coordinator meeting in the workbench under …
KESETT – Welcoming Our New Site Manager
Please join the SIREN CCC in welcoming our new KESETT Site Manager, Vincent Cervantes. Vincent will be the primary point of contact for KESETT site management questions. His contact is …
Overview
Ketamine add-on therapy for Established Status Epilepticus Treatment Trial (KESETT)
A multicenter, randomized, blinded study of treatment of patients with benzodiazepine-refractory status epilepticus in the emergency department, with either levetiracetam or levetiracetam combined with 1 mg/kg or 3 mg/kg dose ketamine to determine which treatment leads to more effective control of status epilepticus.
Contact
Emergency 24-Hour Study Hotline:
To be announced
Education (training, website access, material development, technical support):
Courtney Miller ([email protected]) – Education Coordinator, or [email protected]
WebDCU Support (user account requests, technical support, CRF completion):
Sara Meyer ([email protected]) (843) 792-1599 & Riley Luckmann ([email protected]) (843) 792-1599
Site Management & General Inquiries:
Vincent Cervantes ([email protected]) or [email protected]
Finances:
Valerie Stevenson ([email protected])